Blue-Light Bladder Cancer Examination Proposed for 510(k) Pathway: FDA Lowers Medical Device Market-Entry Barrier

Bladder tumors can sometimes be difficult to identify under conventional white-light endoscopy, particularly flat carcinoma in situ with indistinct margins. The U.S. Food and Drug Administration (FDA) is now proposing to revise the regulatory classification of blue-light cystoscopy systems, potentially lowering the procedural barrier for new devices to enter the U.S. market and thereby expanding the availability of this type of adjunctive examination.

The proposal covers systems under product code OAY. Patients first receive an approved optical imaging agent, after which physicians use blue light to observe suspicious tissue that fluoresces, in conjunction with conventional white-light cystoscopy. It is not a standalone tool intended to replace white-light examination, but is used to assist in bladder cancer detection, surveillance, and the identification of carcinoma in situ.

These devices are currently classified as Class III medical devices, the highest-risk category, and in principle require premarket approval (PMA). The FDA recommends reclassifying them as Class II, establishing “cystoscope system for assisting in the detection of bladder cancer” as the regulatory name, and requiring special controls and 510(k) premarket notification. If the final order is adopted, manufacturers would primarily need to demonstrate that a new product is substantially equivalent to a legally marketed predicate device, rather than undergoing the full PMA process on a case-by-case basis.

The FDA said its determination was based on existing PMA data, peer-reviewed literature, a 2009 expert advisory meeting, and postmarket information. As of April 30, 2026, the agency had identified 11 unique medical device event reports, as well as one labeling-related recall. The FDA was not aware of any record of injury resulting from that recall, and the overall data did not indicate a significant new safety signal.

However, the number of reports cannot itself be directly converted into an incidence rate, and public data do not provide the total number of device uses as a denominator. Class II classification also does not mean exemption from review: the FDA may still address risks including missed diagnoses, misinterpretation, and system operation through performance testing, labeling, compatibility requirements, and other special controls.

The process can be traced back to a reclassification petition for product code OAY. The FDA’s official index shows that Karl Storz Regulatory Affairs Director Leigh Spotten submitted the relevant application in 2022; in April this year, Photocure disclosed that the FDA would initiate a separate formal process under its own authority. In other words, the industry petition advanced the discussion, but the current proposal was put forward by the FDA pursuant to law, and the final outcome still depends on the subsequent regulatory process.

If the reclassification is finalized, the more streamlined 510(k) pathway could attract more manufacturers and facilitate updates to existing devices, reducing barriers for hospitals seeking to acquire blue-light systems. Whether this ultimately translates into broader clinical use will still depend on whether new products pass review, as well as healthcare institutions’ procurement, operator training, and access to imaging agents. What is changing at present is the regulatory pathway, not the standards for bladder cancer diagnosis themselves.